Hong Chen is a Principal Investigator at Boston Children's Hospital and an Associate Professor of Surgery at Harvard Medical School . Their work bridges vascular biology, computational methods, and metabolic disease research, with a focus on atherosclerosis, diabetes, and lymphatic system regulation. Harvard Medical School, Department of Surgery Boston Children's Hospital, Chen Lab Research spans endothelial cell signaling , single-cell RNA sequencing , and metabolite-mediated communication . Key areas include: FOXM1/Dab2 pathways in diabetic wound healing Epsin proteins in atherosclerosis and lipid metabolism Development of MEBOCOST algorithm for metabolite-CRC detection CXCL12/CXCR4 in neuro-lymphatic communication VEGFR3 and caveolae inhibition in lymphatic fate determination Recent publications highlight machine learning applications for cell identity genes, metabolite signaling in adipose tissue, and transcriptional regulators in cardiovascular disease. No explicit scientific awards or student advisement details were found in the provided text.
Marguerite Buzza, PhD, serves as a Researcher in the Department of Pharmacology & Physiology at the University of Maryland School of Medicine, where she has been a faculty member since 2012. Her research focuses on membrane-anchored serine proteases, particularly Matriptase and Granzyme B, and their physiological roles in intestinal barrier integrity, immune regulation, and inflammatory diseases. She actively contributes to the Center for Vascular and Inflammatory Diseases (CVID) through seminar organization and collaborative research. Education: PhD in Medicine (Biochemistry and Molecular Biology), Monash University, Victoria, Australia, 2004 Dr. Buzza's research investigates how serine proteases regulate epithelial barrier function, with emphasis on Matriptase's critical role in preventing Inflammatory Bowel Diseases (IBD) like Crohn's Disease and Ulcerative Colitis. Her work demonstrates that Matriptase deficiency leads to impaired intestinal barrier recovery during colitis and identifies Prostasin as its essential upstream activator. She explores cytokine-mediated disruption of the Matriptase-Prostasin cascade and its implications for IBD pathogenesis, bridging molecular mechanisms with clinical outcomes. Analysis of her 15 most recent publications reveals consistent focus on protease biology across biochemistry, immunology, and gastroenterology. Key themes include proteolytic cascades in barrier regulation (7 articles), disease mechanisms in IBD (5 articles), and novel therapeutic targets like testisin in oncology (3 articles). Her work demonstrates increasing translational emphasis since 2010, with 60% of publications directly addressing disease models or therapeutic applications. Scientific Awards: FASEB SRC Poster Award for outstanding poster presentation at the FASEB SRC Proteases in Hemostasis & Vascular Biology conference (2015, Keystone, CO) Dr. Buzza mentors four doctoral candidates—Gregory Conway, Tierra Johnson, Raymond Peroutka, and Nisha Pawar—and serves on thesis committees for Conway and Peroutka in the Molecular Medicine Program. Her research is supported by NIH grants investigating protease-mediated barrier dysfunction in IBD, with recent funding focusing on Matriptase-Prostasin signaling pathways. She also serves as ad hoc reviewer for the Journal of Biological Chemistry, American Journal of Physiology, and other high-impact journals. She leads an active laboratory within the Department of Pharmacology & Physiology, utilizing molecular, cellular, and murine models to study protease functions. As co-organizer of the CVID Seminar Series, she fosters interdisciplinary collaboration between vascular biology and inflammatory disease researchers, facilitating knowledge exchange on protease roles in hemostasis and tissue repair.
Biju Bhargavan, PhD , is an Instructor in the Department of Anesthesiology at the University of Nebraska Medical Center (UNMC), affiliated with the College of Medicine. His research focuses on molecular mechanisms of HIV-1-induced blood-brain barrier (BBB) dysfunction, neuroinflammation, and epigenetic regulation in neuroAIDS pathogenesis. PhD in Pharmacology, Central Drug Research Institute, Lucknow, India (2009) Research Interests: Dr. Bhargavan investigates how HIV-1 subtypes differentially affect BBB integrity through viral proteins, adhesion molecules, cytokines, and chemokine receptors. His work explores TLR signaling, epigenetic modifications (e.g., DNA methylation, histone acetylation), and nanomedicine-based drug delivery systems for CNS targeting. Scientific Contributions: He holds multiple international patents for pharmaceutical compositions targeting bone disorders using Butea isoflavones. His publications reveal key insights into: HIV-1 Tat protein interactions with TLR4/6 in neuroinflammation Epigenetic regulation of LEDGF in aging and oxidative stress TLR3-mediated IL-6 expression via JNK/TAK1 pathways SARS-CoV-2 spike protein effects on endothelial injury and coagulation Methodologies: Utilizes in vitro BBB models, humanized mice, and molecular signaling analyses to study viral neuropathogenesis and develop antiretroviral nanotherapeutics.
Dr Leonid Nikitenko is a Lecturer in Biomedical Sciences at Hull York Medical School, University of Hull. His interdisciplinary research bridges biology, medicine, and computer science, focusing on endothelial cell roles in chronic diseases including cancer, idiopathic pulmonary fibrosis (IPF), cardiovascular disorders, and lymphoedema. He employs platform technologies like proteomics and genomics for early cancer detection, with a dedicated website ( www.endothelial-cell.com ) showcasing his work. Former lab alumni now hold positions at top institutions including Oxford, Warwick, and London-based hospitals and biotech companies. His research spans: Endothelial cell reprogramming in disease states Angiogenesis mechanisms in cancer and fibrosis Proteomic and genomic profiling for diagnostic signatures Coagulation-cancer axis in tumor vascularization GPCR signaling in vascular pathologies Recent publications highlight his work in: Quantitative proteomics of CLR interactome (2024) MAPK phosphorylation dynamics in endothelial cells (2023-2024) Single-cell RNA sequencing of aging lung endothelium in IPF (2022) Mechanistic studies on anticoagulant therapies in oncology (2019) Dr Nikitenko's work at the Hull Molecular Imaging Centre contributes to understanding vascular biology across multiple pathologies, with translational applications in diagnostic development and therapeutic targeting.
Michael T. Lin is an Associate Professor of Neuroscience at the Brain and Mind Research Institute and Associate Professor of Neurology at Weill Cornell Medical College, positions he has held since 2012. His academic background includes an A.B. from Harvard University (1988) and an M.D. from the University of California, San Francisco School of Medicine (1992). Dr. Lin's research focuses on molecular mechanisms of neurodegenerative diseases, with emphasis on: Alzheimer's disease pathology and amyloid processing Mitochondrial dysfunction in Parkinson's disease Synaptic plasticity and ion channel regulation Therapeutic strategies for neuroprotection Clinical biomarkers for prodromal neurodegeneration His publication record reveals consistent focus on Alzheimer's pathogenesis (amyloid dynamics, synaptic impairment), Parkinson's disease (mitochondrial DNA mutations), and neurotherapeutic development. Recent clinical work explores neurodevelopmental diversity and non-cognitive biomarkers in neurodegeneration. Current research support includes a 2023-2028 NIH/NIA grant as Principal Investigator for Longitudinal Follow up of Clinical Trial Participants For Brain Donation . No advising relationships or scientific awards are documented.
Sunghee Cho, Ph.D., is a Professor of Neuroscience at Weill Cornell Medicine and serves as Lab Director at the Stroke Neuroimmunology Laboratory at Burke Neurological Institute. She is also affiliated with the Brain and Mind Research Institute and holds editorial roles at prominent journals including Stroke and Cerebral Blood Flow/Metabolism. Ph.D. in Neuroscience, Weill Cornell Medical College M.S. in Human Nutrition, Cornell University B.S. in Chemistry, Yonsei University Her research focuses on neuron-immune interactions in stroke-induced brain injury and repair mechanisms. Key areas include CD36 receptor signaling, blood-brain barrier dysfunction, monocyte infiltration, and metabolic modulation of stroke outcomes. Current studies investigate obesity's impact on stroke recovery and therapeutic targeting of neuroinflammatory pathways. Recent publications highlight trends in CD36 inhibition for neuroprotection, remote ischemic conditioning, and molecular mechanisms linking metabolic disorders with stroke severity. Collaborative work with the Ratan Lab explores ER stress pathways in neurodegeneration. Fellow of American Heart/Stroke Association (FAHA) NIH Neural Oxidative Metabolism and Death (NOMD) Study Section member Editorial roles at Stroke journals Her research is funded by NINDS, NHLBI, American Heart Association, Sanofi, and the Burke Foundation. She leads the Preclinical Stroke Modeling program at Burke Neurological Institute and collaborates with European research consortia.
Dr. Rino Ragno is a Full Professor at the Department of Chemistry and Pharmaceutical Technology , Sapienza University of Rome. His academic career spans decades of innovation in drug design , computational chemistry , and machine learning applications for chemical-biological systems. He teaches courses like Pharmaceutical and Toxicological Chemistry I and Computational Medicinal Chemistry , accessible via elearning.uniroma1.it. Research focuses on small molecule design , natural product analysis , and predictive modeling Developed the 3D-QSAR PORTAL for molecular modeling and drug discovery Active in essential oil characterization for antimicrobial, anticancer, and anti-inflammatory applications Recent publications emphasize machine learning classification models for essential oil activity prediction, anti-Bcl-2 cancer therapies , and AI-driven drug discovery . His lab employs multidisciplinary approaches combining experimental data with computational analysis to identify bioactive compounds and optimize drug candidates. The 3D-QSAR PORTAL, a free non-profit web platform, enables conformational analysis , molecular docking , and 3D-QSAR modeling accessible across electronic devices. Current projects include essential oil-based biocides for cultural heritage conservation and nanoemulsion formulations for drug delivery systems.
Charles Cranfield is an Associate Professor in the School of Life Sciences at the University of Technology Sydney (UTS). He leads the Membrane Biophysics Group and has held roles such as Director of HDR Programs (2021–present) and Program Director for Biomedical Science degrees. His research focuses on membrane biophysics, ion channels, and biosensor development, with applications in medical diagnostics and disease studies. He has pioneered technologies like the world’s first nonlinear endoscope and lipid-based biosensors for detecting diseases like inflammatory bowel disorder. Cranfield earned his PhD in Biophysics from Swinburne University of Technology and completed postdoctoral work in the UK and Germany, including Marie Curie Fellowships. His academic career includes leadership roles in curriculum design and research administration. Education: BSc (Honours) in Pharmacology (Monash University, 1996), PhD in Biophysics (Swinburne University of Technology, 2002). Key research areas include membrane-ion interactions, lipid-peptide dynamics, and diagnostic device innovation. He collaborates internationally on projects funded by grants exceeding $15M, including roles as team leader and discipline deputy. Awards include Marie Curie Fellowships and recognition for discoveries in biogenic magnetite and ion channel clustering. Leadership: Director of HDR Programs (Science Faculty), Program Director (Medical Science & Advanced Science) Grants: ARC Research Hub for Integrated Device for End-user Analysis at Low-levels (2017–2023) Service: Peer review for journals like Journal of Colloid and Interface Science , member of the Biophysical Society Current lab activities include developing novel biosensors for lipase activity and phospholipase detection. His team investigates mechanisms of antimicrobial resistance and ion transport in biological membranes, with applications in COPD and IBD diagnostics.
Associate Professor Kristine McGrath is affiliated with the University of Technology Sydney’s School of Life Sciences, within the Faculty of Science. She holds leadership roles as Program Director of Biotechnology programs and Chair of the Institutional Biosafety Committee (IBC). Her research focuses on cardiovascular and endocrine diseases, including therapeutic targets for atherosclerosis, heart failure, and preeclampsia, with recent expansions into air pollution’s impact on dementia and cardiovascular health. She employs innovative 3D bioprinting and cell culture techniques. McGrath has a PhD from the University of Sydney and completed postdoctoral work at the Heart Research Institute. She is a recipient of the CSANZ Ralph Reader Prize for her PhD work. Education: Bachelor of Science (Honours) in Biochemistry, University of Western Australia PhD in Molecular Pathways of Androgen Action in Cardiovascular Systems, University of Sydney Research Interests: Cardiovascular disease mechanisms, endocrine regulation, inflammatory pathways, 3D modeling of placental and cardiac tissues, and environmental health impacts on cardiovascular systems. She explores therapeutic strategies using anti-inflammatory agents and nanotechnology-based interventions. Grants & Collaborations: McGrath leads funded projects on biomaterials for stents, anti-inflammatory drug combinations, and placental models for preeclampsia. She collaborates with industry partners like Insitugen Limited and Plasmaide Global Pty Ltd. Labs & Teams: Active member of UTS’ Climate Change & Health Research Collaborative and Women & Children’s Health Research Collaborative. Engages in interdisciplinary projects combining biotechnology and clinical research.
Lachlan Kelsey is an Adjunct Research Fellow at the UWA Medical School, affiliated with the UWA Centre for Medical Research and the Harry Perkins Institute of Medical Research. His work focuses on hemodynamics, cardiovascular disease mechanisms, and medical device innovation. He holds a PhD and has contributed to over 34 peer-reviewed publications since 2015. His research interests include computational fluid dynamics (CFD), vascular physiology, and translational medical engineering. Key areas of study involve endovascular aneurysm dynamics, coronary plaque activity, placental vascular networks, and peripheral intravenous catheter design. His work addresses clinical challenges such as aortic dissection repair, microgravity-induced circulatory changes, and pandemic-related PPE manufacturing. Notable contributions include developing novel CFD models for predicting aneurysm progression and co-inventing a peripheral IV catheter design that reduced failure rates in porcine models. His 2021 Western Australian Innovator award recognized advancements in cardiovascular device innovation. Collaborations span institutions globally, with projects funded by health research grants. Supervision includes one doctoral student completing a thesis on vascular access technologies. His lab integrates biomedical engineering, clinical imaging, and mechanobiology to advance personalized vascular care.
Dr. David Van Reyk is a Senior Lecturer in Pathophysiology at the School of Life Sciences, University of Technology Sydney (UTS). He has held this position since 2000 and has contributed significantly to research in environmental health, oxidative stress, and educational pedagogy. His roles include Director of Student Mobility and Engagement (2015–2020) and involvement in Indigenous Education initiatives. His research focuses on the impacts of environmental toxins (e.g., PM2.5, e-cigarette vapour) on health, particularly neurodevelopmental and pulmonary effects, with a strong emphasis on sex-dependent outcomes. He has also pioneered experiential learning methods in undergraduate science education, such as simulation-based case studies. His work bridges biomedical research and educational strategy, reflecting a commitment to both scientific discovery and pedagogical innovation. Key research contributions include studies on maternal exposure to air pollutants, mechanisms of oxidative stress in atherosclerosis, and cross-cultural comparisons of remote learning during the pandemic. He has collaborated widely, with over 55 publications. His educational initiatives have emphasized active learning and the application of clinical simulations to enhance student engagement and understanding of complex physiological concepts.
Charalambos Antoniades is the British Heart Foundation Chair of Cardiovascular Medicine and Professor of Cardiovascular Medicine at the University of Oxford's Radcliffe Department of Medicine. He leads the Acute Multidisciplinary Imaging and Interventional Centre (AMIIC) and serves as Deputy Head of the Division of Cardiovascular Medicine. His research focuses on the cross-talk between adipose tissue and the cardiovascular system, leveraging artificial intelligence and advanced imaging to develop precision diagnostics and therapies. Antoniades' work integrates translational research, combining bench-to-bedside approaches. Key projects include the Oxford Heart Vessels & Fat (ox-HVF) cohort and the Oxford Academic cardiovascular Computed Tomography (OXACCT) program. His lab pioneered the Fat Attenuation Index (FAI), a biomarker for coronary inflammation, validated in large-scale studies like the CRISP-CT collaboration with Erlangen University and Cleveland Clinic. Research interests span adipose-derived signaling molecules, redox biology, and AI-driven radiotranscriptomics. He has led randomized trials assessing therapies like canagliflozin and dipeptidyl peptidase 4 inhibitors. Clinical roles include Honorary Consultant Cardiologist and Chair of the British Atherosclerosis Society. His articles highlight advancements in coronary inflammation detection, AI applications, and molecular mechanisms linking obesity to cardiovascular disease. Collaborations span institutions globally, emphasizing clinical translation and risk prediction.
Ana Maria Porras is an Assistant Professor in the J. Crayton Pruitt Family Department of Biomedical Engineering at the University of Florida , part of the Herbert Wertheim College of Engineering . She leads the Tissue-Microbe Interactions Lab , focusing on engineering in vitro models to study human-microbe interactions in contexts of the microbiome, global health, and infectious disease. Her work bridges biomedical engineering with inclusive science communication, particularly in multilingual outreach. Education: B.S., Biomedical Engineering, University of Texas at Austin, 2011 M.S. & Ph.D., Biomedical Engineering, University of Wisconsin-Madison, 2013–2016 Research Interests: Dr. Porras investigates how microbes interact with human extracellular matrices to drive disease, with emphasis on geographic microbiome variations and their implications for enteric infections. She also develops biomaterial-based models of calcific aortic valve disease and explores fibrosis mechanisms. Her science communication work emphasizes equitable access to STEM knowledge, leveraging multilingual strategies and engaging diaspora communities through platforms like Clubes de Ciencia Colombia . Publications Trends: Her recent work spans biomaterial modeling of cardiovascular diseases, microbiome-driven pathogenesis, and DEI initiatives in academia. She frequently publishes on equitable hiring strategies, global health equity, and science communication frameworks. Awards: AAAS Early Career Award for Public Engagement with Science (2024) UF International Center Global Fellow (2021) Cornell Presidential Postdoctoral Fellow (2019–2022) AAAS IF/THEN Ambassador (2019–2021) Advising & Grants: While no formal student advisees are listed, her lab focuses on interdisciplinary training. She has secured grants supporting DEI initiatives, microbiome research, and science communication. Labs/Teams: The Tissue-Microbe Interactions Lab collaborates with global partners on microbiome projects and hosts the Clubes de Ciencia Colombia to empower Latinx scientists through community-building and mentorship.
Dr. Malachy O'Rourke is an Assistant Professor and Programme Director for the ME Mechanical Engineering Degree Programme at the School of Mechanical and Materials Engineering, University College Dublin. His expertise spans cardiovascular biomechanics, aerodynamics, and fluid mechanics. He leads the cardiovascular biomechanics laboratory, which integrates in vitro experimentation (e.g., heart simulators, 3D printing, particle image velocimetry) with computational methods (CFD, FEA, fluid-structure interaction). His research focuses on heart valve disease, abdominal aortic aneurysms, and aerodynamic drag reduction for vehicles. Dr. O'Rourke has been recognized with prestigious awards, including the IMechE Thomas Hawksley Gold Medal (2012) and Duncan Dowson Prize (2012), both for his work on hemodynamics and thrombus deposition in abdominal aortic aneurysms. Education: B.E. and Ph.D. in Mechanical Engineering from Queen's University Belfast (1991, 1996). Professional experience includes roles at GEC Alstom (gas turbine design) and postdoctoral research at Queen's University Belfast. He has authored over 50 publications and secured grants totaling €multi-million, including studies on tetralogy of Fallot and coarctation of the aorta. His teaching includes fluid mechanics modules at undergraduate and postgraduate levels, as well as a biofluid mechanics course for biomedical engineering students. Research interests combine cardiovascular systems (e.g., mitral/tricuspid valve dynamics, cerebral aneurysms) and low-speed aerodynamics (e.g., drag reduction on emergency vehicles, flatbed trailers). His lab's in vitro capabilities include right/left heart simulators, while computational tools model complex hemodynamic phenomena. Recent work explores novel drag-reduction devices and the interplay of shear stress and hypoxia in pulmonary endothelial dysfunction. Awards: IMechE Gold Medal, Duncan Dowson Prize, UCD Equip 2023 Award Grants: €1.8M+ in funding for cardiovascular biomechanics and aerodynamic research Advising: Supervised PhD students Dr. James McCullough (AAA hemodynamics) and Dr. Sinead Kelly (thrombus growth mechanics)
Carol Aherne is an Assistant Professor at University College Dublin's School of Medicine, with prior experience as an Assistant Professor and Research Instructor at the University of Colorado Anschutz Medical Campus. Her research focuses on epithelial barrier dysfunction in inflammatory bowel disease (IBD), investigating signaling molecules that promote epithelial repair and regulate immune responses. She holds a BSc and PhD from University College Dublin, and a Professional Certificate in University Teaching and Learning. Her academic roles include coordinating modules like Experimental Physiology and Principles of Physiology, and she serves as Chair of the School of Medicine's Athena Swan/EDI committee and Vice Chair of the Physiology Teaching and Learning Committee. Key research interests include adenosine receptor signaling, regulatory T-cell induction, and mucosal immunology. Recent work highlights the role of heat shock factor 1 in T-cell regulation and the protective effects of Muc5ac in colitis. Her studies frequently employ murine models to explore therapeutic strategies for IBD. Active grants include investigating epithelial netrin-1's role in mucosal healing and targeting mucin-mediated mechanisms. Her lab collaborates on projects involving organoids for IBD modeling and light-mediated cardiovascular protection. Carol has supervised multiple PhD and MD thesis students and contributes to interdisciplinary research teams exploring inflammation, epithelial biology, and translational medicine.
